5-cyclopropyl-1H-pyrazole-3-carboxylic acid amide | 401629-05-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-cyclopropyl-1H-pyrazole-3-carboxylic acid amide
• 英文别名: 5-cyclopropyl-1H-pyrazole-3-carboxamide
• CAS: 401629-05-8
• 化学式: C₇H₉N₃O
• mdl: MFCD16619778
• 分子量: 151.168
• InChiKey: OQUJEFJLUNVUBM-UHFFFAOYSA-N

物化性质

• 沸点：
  415.6±33.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  71.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-cyclopropyl-1H-pyrazole-3-carboxylic acid amide 、 溴甲苯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-benzyl-5-cyclopropyl-1H-pyrazole-3-carboxylic acid amide
  参考文献：
  名称：

  Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a

  摘要：

  A series of 5-alkyl pyrazole-3-carboxylic acids were prepared and found to act as potent and selective agonists of the human GPCR, GPR109a, the high affinity nicotinic acid receptor. No activity was observed at the highly homologous low affinity niacin receptor, GPR109b. A further series of 4-fluoro-5-alkyl pyrazole-3-carboxylic acids were shown to display similar potency. One example from the series was shown to have improved properties in vivo compared to niacin. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.101
• 作为产物：
  描述：

  5-环丙基-1H-吡唑-3-羧酸乙酯 在 氨 作用下， 以 甲醇 为溶剂， 以39%的产率得到5-cyclopropyl-1H-pyrazole-3-carboxylic acid amide
  参考文献：
  名称：

  Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a

  摘要：

  A series of 5-alkyl pyrazole-3-carboxylic acids were prepared and found to act as potent and selective agonists of the human GPCR, GPR109a, the high affinity nicotinic acid receptor. No activity was observed at the highly homologous low affinity niacin receptor, GPR109b. A further series of 4-fluoro-5-alkyl pyrazole-3-carboxylic acids were shown to display similar potency. One example from the series was shown to have improved properties in vivo compared to niacin. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.101

文献信息

• [EN] N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES<br/>[FR] HÉTÉROCYCLYLE CARBOXAMIDES N-SUBSTITUÉS
  申请人：NOVARTIS AG

  公开号：WO2013038390A1

  公开（公告）日：2013-03-21

  A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Ra, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in the treatment of inflammatory or obstructive airways diseases or mucosal hydration, including, for example cystic fibrosis. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  一种符合公式I的化合物及其药用可接受的盐和溶剂化合物，其中R1、R2、R3、Ra、A、B、D和E均如本文所定义。这些化合物调节CFTR的活性，并且在治疗炎症性或阻塞性气道疾病或粘膜水合方面具有用处，例如囊性纤维化。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• [EN] PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSES PYRAZOLE POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：PFIZER PROD INC

  公开号：WO2004033434A1

  公开（公告）日：2004-04-22

  The invention provides compounds of Formula (I): wherein R1,R2,R3, R4,R6,R7, R8 and A are as defined. Compounds of formula (I) have activity inhibiting production of Aβ-peptide. The invention also provides pharmaceutical compositions and methods for treating diseases, for example Alzheimer's disease, in mammals comprising compounds of Formula (I).

  该发明提供了Formula (I)的化合物：其中R1、R2、R3、R4、R6、R7、R8和A的定义如上所述。 Formula (I)的化合物具有抑制Aβ-肽产生的活性。 该发明还提供了包含Formula (I)化合物的治疗药物组合物和方法，用于治疗哺乳动物的疾病，例如阿尔茨海默病。
• [EN] NOVEL CB 1 RECEPTOUR INVERSE AGONISTS<br/>[FR] NOUVEAUX AGONISTES INVERSES DU RECEPTEUR CB 1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004060870A1

  公开（公告）日：2004-07-22

  The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment . and/or prophylaxis of diseases which are associated with the modulation of CB 1 receptors.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、R6、m和X如描述和索赔中定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与CB1受体调节相关的疾病。
• Pyrazole compounds for treatment of neurodegenerative disorders
  申请人：——

  公开号：US20040142997A1

  公开（公告）日：2004-07-22

  The invention provides compounds of Formula I: 1 wherein R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8, and A are as defined. Compounds of formula I have activity inhibiting production of A&bgr;-peptide. The invention also provides pharmaceutical compositions and methods for treating diseases, for example Alzheimer's disease, in mammals comprising compounds of Formula I.

  该发明提供了公式I的化合物：1其中R1、R2、R3、R4、R6、R7、R8和A的定义如上所述。公式I的化合物具有抑制Aβ-肽生成的活性。该发明还提供了含有公式I化合物的药物组合物和治疗哺乳动物疾病的方法，例如阿尔茨海默病。
• Novel CB 1 receptor inverse agonists
  申请人：——

  公开号：US20040167129A1

  公开（公告）日：2004-08-26

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

  本发明涉及式（I）1的化合物，其中R1、R2、R3、R4、R5、R6、m和X如描述和权利要求中所定义，并且其制药可接受的盐。这些化合物对于治疗和/或预防与CB1受体调节相关的疾病是有用的。